Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority to DO2007000117ApriorityCriticalpatent/DOP2007000117A/en
Publication of DOP2007000117ApublicationCriticalpatent/DOP2007000117A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una composición farmaceutica para la anticoncepción contiene en una dosis diaria - 2,0 mg o 1,5 mg de 17a-cianometil-17-1&-hidroxiestra-4,9-dien3-ona (dienogest) y 0,015 mg de 17a-etinilestradiol (etinilestradiol) y (6S)-5metiltetrahidrofolato, con preferencia como sal de calcio del acido (6S)-5metiltetrahidrof6lico (metafolina) junto con uno o varios excipientes/vehiculos farmaceuticamente aceptables. La composición farmaceutica segun la invención realiza una anticoncepción oral y es tambien un agente para reducir el riesgo de malformaciones congenitas. Por otra parte, un kit contiene 21 unidades de dosis diarias de la composición farmaceutica y 7 unidades de dosis diarias que contienen solo (6S)-5-metiltetrahidrofolato, incluso con preferencia metafolina.A pharmaceutical composition for contraception contains in a daily dose - 2.0 mg or 1.5 mg of 17a-cyanomethyl-17-1 & -hydroxystra-4,9-dien3-one (dienogest) and 0.015 mg of 17a-ethinyl estradiol ( ethynylestradiol) and (6S) -5-methyltetrahydrofolate, preferably as calcium salt of (6S) -5-methyltetrahydroflucic acid (metapholine) together with one or more pharmaceutically acceptable excipients / vehicles. The pharmaceutical composition according to the invention performs oral contraception and is also an agent to reduce the risk of congenital malformations. On the other hand, a kit contains 21 units of daily doses of the pharmaceutical composition and 7 units of daily doses containing only (6S) -5-methyltetrahydrofolate, even preferably metapholine.
DO2007000117A2007-07-052007-07-05
PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS
DOP2007000117A
(en)
Contraceptive pharmaceutical composition comprising 5-methyl- (6s) -tetrahydrofolate, estrogens and / or progestagens, optionally vitamin b6 and / or vitamin b2 and adjuvants / vehicles; kit; process to prepare it; use to reduce the risk of diseases and congenital malformations due to folate deficiency (div. sol. 1130-06).
Single-dose pharmaceutical composition containing a) as gestagen 50-90 µg of levonorgestrel and b) as cox inhibitor (cyclooxygenase) 5-60 mg of piroxicam, 50-600 mg of indomethacin or 40-450 mg of diclofenac; and its use to prepare drugs for contraception in an emergency.
Use of gestagens in combination with (6s)-5-methyltetrahydrofolat e for the therapy of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy.
A pharmaceutical composition for enhancing iron levels in blood, comprising iron (iii) polymaltose and another active substance, suitable for iron absorption, selected from calcium folinate pentahydrate, vitamin c or a combination of both
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.